- Home
- PL vs PCRX Comparison
PL vs PCRX Comparison
Compare PL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PL
- PCRX
- Stock Information
- Founded
- PL 2010
- PCRX 2006
- Country
- PL United States
- PCRX United States
- Employees
- PL N/A
- PCRX N/A
- Industry
- PL Aerospace
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PL Industrials
- PCRX Health Care
- Exchange
- PL Nasdaq
- PCRX Nasdaq
- Market Cap
- PL 1.0B
- PCRX 1.1B
- IPO Year
- PL N/A
- PCRX 2011
- Fundamental
- Price
- PL $3.44
- PCRX $24.91
- Analyst Decision
- PL Strong Buy
- PCRX Buy
- Analyst Count
- PL 11
- PCRX 9
- Target Price
- PL $5.79
- PCRX $30.67
- AVG Volume (30 Days)
- PL 4.7M
- PCRX 920.6K
- Earning Date
- PL 03-20-2025
- PCRX 05-06-2025
- Dividend Yield
- PL N/A
- PCRX N/A
- EPS Growth
- PL N/A
- PCRX N/A
- EPS
- PL N/A
- PCRX N/A
- Revenue
- PL $244,352,000.00
- PCRX $700,966,000.00
- Revenue This Year
- PL $15.78
- PCRX $9.77
- Revenue Next Year
- PL $17.22
- PCRX $9.83
- P/E Ratio
- PL N/A
- PCRX N/A
- Revenue Growth
- PL 10.72
- PCRX 3.85
- 52 Week Low
- PL $1.67
- PCRX $11.16
- 52 Week High
- PL $6.71
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- PL 37.38
- PCRX 55.86
- Support Level
- PL $3.15
- PCRX $23.93
- Resistance Level
- PL $4.03
- PCRX $25.08
- Average True Range (ATR)
- PL 0.25
- PCRX 0.97
- MACD
- PL -0.00
- PCRX 0.20
- Stochastic Oscillator
- PL 41.78
- PCRX 76.05
About PL Planet Labs PBC
Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.